Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?

Concomitant neuropathological hallmarks of Alzheimer’s Disease (AD) are common in the brains of people with Parkinson’s disease (PD). Furthermore, AD biomarkers are associated with cognitive decline and dementia in PD patients during life. Here, we highlight the considerable overlap between AD and P...

Descripción completa

Detalles Bibliográficos
Autores principales: Tropea, Thomas F., Chen-Plotkin, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472048/
https://www.ncbi.nlm.nih.gov/pubmed/34575610
http://dx.doi.org/10.3390/jpm11090834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472048/
https://www.ncbi.nlm.nih.gov/pubmed/34575610
http://dx.doi.org/10.3390/jpm11090834

Ejemplares similares